NorthSpeed Biotech - Company finances
|
EUR
|
2022
From: 2022-07-15
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|
|
Financial data
|
||||
| Sales revenue | 37,543 | 214,769 | 331,392 | 430,444 |
| Profit before tax | 5,984 | 32,672 | 68,091 | 88,585 |
| Net profit | 5,984 | 31,038 | 59,168 | 75,652 |
| Equity | 6,983 | 38,021 | 59,947 | 95,884 |
| Liabilities | 1,614 | 16,594 | 18,114 | 23,717 |
| Non-current assets | 0 | 5,000 | 8,835 | 11,234 |
| Current assets | 8,597 | 49,615 | 69,226 | 108,367 |
| Total assets | 8,597 | 54,615 | 78,061 | 119,601 |
|
Taxes paid
|
||||
| STI taxes | - | 33,154 | 53,927 | 88,761 |
|
Financial indicators
|
||||
| Revenue change y/y | - | +472.1% | +54.3% | +29.9% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 69.6% | 56.8% | 75.8% | 63.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 85.7% | 81.6% | 98.7% | 78.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 15.9% | 14.5% | 17.9% | 17.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 15.9% | 15.2% | 20.5% | 20.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.2 | 0.4 | 0.3 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | 430,444 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
NorthSpeed Biotech - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-10-30 | 2025-11-30 | 8.51 |
| 2025-06-24 | 2025-09-30 | 0.02 |
| 2024-06-12 | 2024-06-30 | 307.85 |
| 2024-06-04 | 2024-06-11 | 237.54 |
NorthSpeed Biotech - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-04-24 | 2026-04-26 | 164.48 |
| 2026-01-15 | 2026-01-15 | 1607.72 |
| 2025-02-01 | 2025-02-01 | 0.04 |
| 2025-01-30 | 2025-01-31 | 798.96 |
| 2025-01-29 | 2025-01-29 | 823.56 |
| 2025-01-28 | 2025-01-28 | 1662.56 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
NorthSpeed Biotech, MB (code 306115521) is a Small partnership engaged in activities of agents involved in the wholesale of other particular products. In 2025, the company generated revenue of €430.4K and net profit of €75.7K, with a profit margin of 17.6%. Revenue increased by 29.9% year on year, and over the last two years it rose by 100.4% from the 2023 level of €214.8K. Profitability also strengthened during this period, with net profit increasing from €31.0K in 2023 to €59.2K in 2024 and €75.7K in 2025. The balance sheet expanded from €54.6K in 2023 to €119.6K in 2025, supported by equity growth from €38.0K to €95.9K. Liabilities remained modest at €23.7K in 2025, and the equity ratio stood at 80.2%. The company reported a debt-to-equity ratio of 0.25, asset turnover of 3.60x, ROE of 78.9% and ROA of 63.2%. Revenue per employee was €430.4K, while profit per employee reached €75.7K.